Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analysed the earning revision of component stocks of CSI 300 in the past month.</li>
<li>We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.</li>
<li>We highlighted EPS revision on INDUSTRIAL BANK, YANTAI JEREH OILFIELD SERVICES, XIAMEN TUNGSTEN, KUNLUN TECH, CHONGQING ZHIFEI BIOLOGICAL PRODUCTS, GIANT NETWORK, CHINA SHENHUA ENERGY, Xinjiang Daqo.</li>
</ul>


We analysed the earning revision of component stocks of CSI 300 in the past month.
We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.
We highlighted EPS revision on INDUSTRIAL BANK, YANTAI JEREH OILFIELD SERVICES, XIAMEN TUNGSTEN, KUNLUN TECH, CHONGQING ZHIFEI BIOLOGICAL PRODUCTS, GIANT NETWORK, CHINA SHENHUA ENERGY, Xinjiang Daqo.


CSI 300 Index Earning Revision (Jun): INDUSTRIAL BANK, YANTAI JEREH OILFIELD SERVICES, KUNLUN TECH

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Thematic (Sector/Industry)

1. Industry viewpoints: <ul>
<li>A new policy was released to clarify the scope and price of medical insurance payments for online healthcare service, which help open up the market scale of digital healthcare business.</li>
<li>Currently, some of the so-called "innovative drugs" in China are still far from real innovation, such as the PD-1 market.</li>
<li>Polypeptide drugs account for a small share in the global biomedical market, but they are developing rapidly.</li>
</ul>2. Company news:News from Wondfo Biotech, CSPC and Sino Biopharm about the new products for COVID-19 antigen tests, clinical progress on new category 1 drug and the new products that pass the consistency evaluation in China.3. Market review:Last week, stock price for healthcare sector in A share decreased 1.36%, while CSI 300 increased 4.05% over the same period of time.4. Risk Disclosure:Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

1. Industry viewpoints: 
A new policy was released to clarify the scope and price of medical insurance payments for online healthcare service, which help open up the market scale of digital healthcare business.
Currently, some of the so-called "innovative drugs" in China are still far from real innovation, such as the PD-1 market.
Polypeptide drugs account for a small share in the global biomedical market, but they are developing rapidly.
2. Company news:News from Wondfo Biotech, CSPC and Sino Biopharm about the new products for COVID-19 antigen tests, clinical progress on new category 1 drug and the new products that pass the consistency evaluation in China.3. Market review:Last week, stock price for healthcare sector in A share decreased 1.36%, while CSI 300 increased 4.05% over the same period of time.4. Risk Disclosure:Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

China and US Equity Analyst

Roger Xie

Cross Asset Strategy

Chinese fund managers have added more tech and pharma stocks than any other sectors in their portfolios in 1Q this year, according to the fund industry disclosure. Their holdings on tech-heavy ChiNext stock (a NASDAQ-style stock exchange in Shenzhen) have soared to above 20%, a four-year high positions. This is in stark contrast that other large-cap stocks are underweighted and underperformed. We believe the positions dispersion will last longer than expected, tech and consumer-oriented stocks will likely outperform in coming quarters.

Chinese fund managers have added more tech and pharma stocks than any other sectors in their portfolios in 1Q this year, according to the fund industry disclosure. Their holdings on tech-heavy ChiNext stock (a NASDAQ-style stock exchange in Shenzhen) have soared to above 20%, a four-year high positions. This is in stark contrast that other large-cap stocks are underweighted and underperformed. We believe the positions dispersion will last longer than expected, tech and consumer-oriented stocks will likely outperform in coming quarters.

China A-Share Strategy: What Are Mutual Funds Buying in 1Q? Tech and Pharma

Index Rebalance

China Tungsten And Hightech Ma / Index Rebalance

China Tungsten And Hightech Ma (000657 CH)

<ul>
<li>CSI confirmed 19 ADDs and 19 DELETEs for the June 2026 rebalance, effective 15 Jun 2026.</li>
<li>ADD gains narrowed to seven positive-bridge names, led by Xiamen Tungsten and China Tungsten. DELETEs fell -4.4% on average.</li>
<li>Historical first-week outcomes were negative on average for both ADD and DELETE, but different subgroup recorded varied performance.</li>
</ul>


CSI confirmed 19 ADDs and 19 DELETEs for the June 2026 rebalance, effective 15 Jun 2026.
ADD gains narrowed to seven positive-bridge names, led by Xiamen Tungsten and China Tungsten. DELETEs fell -4.4% on average.
Historical first-week outcomes were negative on average for both ADD and DELETE, but different subgroup recorded varied performance.


CSI 300 June 2026 Rebalance: Pre-Implementation Update

<ul>
<li>We analysed the earning revision of component stocks of CSI 300 in the past month.</li>
<li>We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.</li>
<li>We highlighted EPS revision on Xinjiang Daqo, TONGWEI, SERES, CHINA VANKE, Wuliangye, YONYOU NETWORK TECHNOLOGY, BANK OF BEIJING, CSSC.</li>
</ul>


We analysed the earning revision of component stocks of CSI 300 in the past month.
We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.
We highlighted EPS revision on Xinjiang Daqo, TONGWEI, SERES, CHINA VANKE, Wuliangye, YONYOU NETWORK TECHNOLOGY, BANK OF BEIJING, CSSC.


CSI 300 Index Earning Revision (May): Xinjiang Daqo, TONGWEI, SERES, CHINA VANKE, Wuliangye, CSSC

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Changchun High-Tech Industry (CHT HK)

CSI 300 Index Earning Revision (Jun): INDUSTRIAL BANK, YANTAI JEREH OILFIELD SERVICES, KUNLUN TECH

We analyzed CSI 300's consensus for Jun 2026 and highlighted changes of EPS in INDUSTRIAL BANK (601166 CH), YANTAI JEREH OILFIELD SERVICES (002353...

Ke Yan, CFA, FRM

China Healthcare Weekly (Nov.6)

This article summarized the new healthcare policy released in China, major industry viewpoints, company news and capital markets review for the...

Xinyao (Criss) Wang

CSI 300 June 2026 Rebalance: Pre-Implementation Update

CSI 300 enters implementation on 15 Jun 2026. We update post-announcement stock performance and discuss implementation trades.

Ke Yan, CFA, FRM

CSI 300 Index Earning Revision (May): Xinjiang Daqo, TONGWEI, SERES, CHINA VANKE, Wuliangye, CSSC

We analyzed CSI 300's consensus for May 2026 and highlighted changes of EPS in Xinjiang Daqo, TONGWEI, SERES, CHINA VANKE, Wuliangye, YONYOU...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

CSI 300 Index Earning Revision (Jun): INDUSTRIAL BANK, YANTAI JEREH OILFIELD SERVICES, KUNLUN TECH

We analyzed CSI 300's consensus for Jun 2026 and highlighted changes of EPS in INDUSTRIAL BANK (601166 CH), YANTAI JEREH OILFIELD SERVICES (002353...

Ke Yan, CFA, FRM

China Healthcare Weekly (Nov.6)

This article summarized the new healthcare policy released in China, major industry viewpoints, company news and capital markets review for the...

Xinyao (Criss) Wang

China A-Share Strategy: What Are Mutual Funds Buying in 1Q? Tech and Pharma

Chinese fund managers have added more tech and pharma stocks than any other sectors in their portfolios in 1Q this year, according to the fund...

Roger Xie

CSI 300 June 2026 Rebalance: Pre-Implementation Update

CSI 300 enters implementation on 15 Jun 2026. We update post-announcement stock performance and discuss implementation trades.

Ke Yan, CFA, FRM

CSI 300 Index Earning Revision (May): Xinjiang Daqo, TONGWEI, SERES, CHINA VANKE, Wuliangye, CSSC

We analyzed CSI 300's consensus for May 2026 and highlighted changes of EPS in Xinjiang Daqo, TONGWEI, SERES, CHINA VANKE, Wuliangye, YONYOU...

Ke Yan, CFA, FRM